TABLE 1.
Baseline characteristics of patients with completely resected ES‐NSCLC receiving platinum‐based adjuvant chemotherapy (pACT) versus no treatment (OBS) after surgery
| Variables | Before IPTW | After IPTW | ||||
|---|---|---|---|---|---|---|
| OBS (n = 2353) | pACT (n = 2347) | SMD | OBS (n = 2353) | pACT (n = 2347) | SMD | |
| (%) | (%) | (%) | (%) | |||
| Male | 60.4 | 53.1 | 0.147 | 56.6 | 56.5 | 0.003 |
| Age (y), mean ± SD | 67.5 ± 10.9 | 60.9 ± 9.8 | 0.638 | 64.8 ± 11.2 | 64.2 ± 10.3 | 0.051 |
| 20–54 | 12.6 | 25.1 | 0.322 | 18.8 | 18.9 | 0.004 |
| 55–64 | 23.0 | 35.7 | 0.283 | 29.5 | 29.5 | <0.001 |
| 65+ | 64.4 | 39.2 | 0.521 | 51.7 | 51.6 | 0.003 |
| Year of diagnosis | ||||||
| 2003–2006 | 10.0 | 6.5 | 0.126 | 8.2 | 8.3 | 0.002 |
| 2007–2010 | 29.7 | 22.2 | 0.172 | 25.1 | 24.7 | 0.009 |
| 2011–2014 | 39.7 | 43.1 | 0.070 | 41.8 | 42.3 | 0.009 |
| 2015–2016 | 20.7 | 28.2 | 0.176 | 24.9 | 24.8 | 0.003 |
| Histological type | ||||||
| ADC | 68.6 | 79.3 | 0.244 | 74.1 | 74.1 | <0.001 |
| SCC | 31.4 | 20.7 | 0.244 | 25.9 | 25.9 | <0.001 |
| Cancer staging | ||||||
| IB + IIA | 54.8 | 32.6 | 0.460 | 43.7 | 43.4 | 0.006 |
| IIB + IIIA | 45.2 | 67.4 | 0.460 | 56.3 | 56.6 | 0.006 |
| Type of surgery | ||||||
| Pneumonectomy or bilobectomy | 7.0 | 5.8 | 0.050 | 6.3 | 6.4 | 0.003 |
| Lobectomy | 77.8 | 80.4 | 0.063 | 78.6 | 78.4 | 0.005 |
| Wedge resection | 15.2 | 13.9 | 0.038 | 15.1 | 15.2 | 0.004 |
| DCCI, mean ± SD | 1.4 ± 1.4 | 1.0 ± 1.2 | 0.293 | 1.2 ± 1.4 | 1.2 ± 1.3 | 0.031 |
| 0 | 29.3 | 41.2 | 0.250 | 35.5 | 35.5 | <0.001 |
| 1 | 34.1 | 34.9 | 0.016 | 34.3 | 34.6 | 0.006 |
| 2+ | 36.6 | 24.0 | 0.277 | 30.2 | 29.9 | 0.006 |
| ECOGPS a | ||||||
| Missing | 49.9 | 37.5 | 0.251 | 43.0 | 42.5 | 0.011 |
| 0 | 29.5 | 40.3 | 0.228 | 35.8 | 35.9 | 0.002 |
| 1+ | 20.6 | 22.2 | 0.038 | 21.2 | 21.6 | 0.010 |
| Follow‐up period (y), mean ± SD | 4.5 ± 3.2 | 4.4 ± 2.7 | 0.023 | 4.4 ± 3.0 | 4.5 ± 2.8 | 0.029 |
Note: Values are presented as the percentage or mean ± SD. SMD > 0.1 indicates the presence of a non‐negligible difference between the two groups.
Abbreviations: ADC, adenocarcinoma; DCCI, Deyo–Charlson comorbidity index; ECOGPS, Eastern Cooperative Oncology Group Performance Score; ES‐NSCLC, early‐stage non–small‐cell lung cancer; IPTW, inverse probability treatment weighting; OBS, observation; pACT, platinum‐based adjuvant chemotherapy; SCC, squamous cell carcinoma; SD, standard deviation; and SMD, standardized mean difference.
a
ECOGPSs were obtained after the year 2011.